MiR-145 inhibits cell migration and increases paclitaxel chemosensitivity in prostate cancer cells

Document Type : Original Article


1 Department of Biological Science, Faculty of Basic Science, Higher Education Institute of Rab-Rashid, Tabriz, Iran

2 Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran

3 Clinical Research Development Unit of Tabriz Valiasr Hospital, Tabriz University of Medical Sciences, Tabriz, Iran


Objective(s): Prostate cancer (PC) is one of the most commonly diagnosed malignancies among men worldwide. Paclitaxel is a chemotherapeutic agent widely used to treat different types of cancer. Recent studies revealed miRNAs control various genes that influence the regulation of many biological and pathological processes such as the formation and development of cancer, chemotherapy resistance, etc.
Materials and Methods: Between three PC cell lines (PC3, DU-145, LNCAP), PC3 showed the lowest miR-145 expression and was chosen for experiments. PC3 cells were treated with paclitaxel and miR-145 separately or in combination. To measure the cell viability, migratory capacity, autophagy, cell cycle progression, and apoptosis induction, the MTT assay, wound-healing assay, and Annexin V/PI apoptosis assay were used, respectively. Moreover, quantitative real-time PCR (qRT-PCR) was employed to measure the expression level of genes involved in apoptosis, migration, and stemness properties.
Results: Obtained results illustrated that miR-145 transfection could enhance the sensitivity of PC3 cells to paclitaxel and increase paclitaxel-induced apoptosis by modulating the expression of related genes, including Caspase-3, Caspase-9, Bax, and Bcl-2. Also, results showed combination therapy increased cell cycle arrest at the sub-G1 phase. miR-145 and paclitaxel cooperatively reduced migration ability and related-metastatic and stemness gene expression, including MMP-2, MMP-9, CD44, and SOX-2. In addition, combination therapy can suppress MDR1 expression.
Conclusion: These results confirmed that miR-145 combined with paclitaxel cooperatively could inhibit cell proliferation and migration and increase the chemosensitivity of PC3 cells compared to mono treatment. So, miR-145 combination therapy may be used as a promising approach for PC treatment.


Main Subjects

1. Golubnitschaja O, Kubatka P, Mazurakova A, Samec M, Alajati A, Giordano FA, et al. Systemic effects reflected in specific biomarker patterns are instrumental for the paradigm change in prostate cancer management: A strategic paper. Cancers 2022; 14:675-698.
2. Panigrahi GK, Praharaj PP, Kittaka H, Mridha AR, Black OM, Singh R, et al. Exosome proteomic analyses identify inflammatory phenotype and novel biomarkers in African American prostate cancer patients. Cancer Med 2019; 8:1110-1123.
3. Rawla P. Epidemiology of prostate cancer. World J Oncol 2019; 10:63.
4. Sumanasuriya S, De Bono J. Treatment of advanced prostate cancer-A review of current therapies and future promise. Cold Spring Harb Perspect Med 2018; 8:a030635-a030647.
5. Quinn D, Sandler H, Horvath L, Goldkorn A, Eastham J. The evolution of chemotherapy for the treatment of prostate cancer. Ann Oncol 2017; 28:2658-2669.
6. Khanna C, Rosenberg M, Vail D. A review of paclitaxel and novel formulations including those suitable for use in dogs. J Vet Intern Med 2015; 29:1006-1012.
7. Zhu L, Chen L. Progress in research on paclitaxel and tumor immunotherapy. Cell Mol Biol Lett 2019; 24:1-11.
8. Otmani K, Lewalle P. Tumor suppressor miRNA in cancer cells and the tumor microenvironment: Mechanism of deregulation and clinical implications. Front Oncol 2021; 11:708765-708779.
9. Annese T, Tamma R, De Giorgis M, Ribatti D. microRNAs biogenesis, functions and role in tumor angiogenesis. Front Oncol 2020;10 :581007-581027.
10. Jebelli A, Oroojalian F, Fathi F, Mokhtarzadeh A, de la Guardia M. Recent advances in surface plasmon resonance biosensors for microRNAs detection. Biosens Bioelectron 2020; 169:112599.
11. Vanacore D, Boccellino M, Rossetti S, Cavaliere C, D’Aniello C, Di Franco R, et al. Micrornas in prostate cancer: An overview. Oncotarget 2017; 8:50240-50251.
12. Jahanafrooz Z, Motamed N, Rinner B, Mokhtarzadeh A, Baradaran B. Silibinin to improve cancer therapeutic, as an apoptotic inducer, autophagy modulator, cell cycle inhibitor, and microRNAs regulator. Life Sci 2018; 213:236-247.
13. Asl ER, Amini M, Najafi S, Mansoori B, Mokhtarzadeh A, Mohammadi A, et al. Interplay between MAPK/ERK signaling pathway and MicroRNAs: A crucial mechanism regulating cancer cell metabolism and tumor progression. Life Sci 2021; 278:119499.
14. Rezaei T, Amini M, Hashemi ZS, Mansoori B, Rezaei S, Karami H, et al. microRNA-181 serves as a dual-role regulator in the development of human cancers. Free Radic Biol Med 2020; 152:432-454.
15. Ye D, Shen Z, Zhou S. Function of microRNA-145 and mechanisms underlying its role in malignant tumor diagnosis and treatment. Cancer Manag Res 2019; 11:969-979.
16. Mansoori B, Mohammadi A, Davudian S, Shirjang S, Baradaran B. The different mechanisms of cancer drug resistance: A brief review. Adv Pharm Bull 2017; 7:339-348.
17. Chou T-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58:621-681.
18. Tun JO, Salvador-Reyes LA, Velarde MC, Saito N, Suwanborirux K, Concepcion GP. Synergistic cytotoxicity of renieramycin M and doxorubicin in MCF-7 breast cancer cells. Mar Drugs 2019; 17:536-561.
19. Bossennec M, Di Roio A, Caux C, Ménétrier-Caux C. MDR1 in immunity: Friend or foe? Oncoimmunology 2018; 7:e1499388-1499398.
20.Dunn MW, Kazer MW. Prostate cancer overview. Semin Oncol Nurs 2011;27:241-250.
21. Sandhu S, Moore CM, Chiong E, Beltran H, Bristow RG, Williams SG. Prostate cancer. Lancet 2021; 398:1075-1090.
22. Ma Y, Yu S, Ni S, Zhang B, Kung ACF, Gao J, et al. Targeting strategies for enhancing paclitaxel specificity in chemotherapy. Front Cell Dev Biol 2021; 9:626910-626916.
23. Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi Y, et al. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem 2010; 285:21496-21507.
24. Li L, Wu C, Zhao Y. miRNA-34a enhances the sensitivity of gastric cancer cells to treatment with paclitaxel by targeting E2F5. Oncol Lett 2017; 13:4837-4842.
25. Xu W, Hua Y, Deng F, Wang D, Wu Y, Zhang W, et al. MiR‐145 in cancer therapy resistance and sensitivity: A comprehensive review. Cancer Sci 2020; 111:3122-3131.
26. Zhu X, Li Y, Xie C, Yin X, Liu Y, Cao Y, et al. MiR‐145 sensitizes ovarian cancer cells to paclitaxel by targeting Sp1 and Cdk6. Int J Cancer 2014; 135:1286-1296.
27. Qian C, Wang B, Zou Y, Zhang Y, Hu X, Sun W, et al. MicroRNA 145 enhances chemosensitivity of glioblastoma stem cells to demethoxycurcumin. Cancer Manag Res 2019; 11:6829-6840.
28. Zheng T-L, Li D-P, He Z-F, Zhao S. MiR-145 sensitizes esophageal squamous cell carcinoma to cisplatin through directly inhibiting PI3K/AKT signaling pathway. Cancer Cell Int 2019; 19:1-15.
29. Frenzel A, Grespi F, Chmelewskij W, Villunger A. Bcl2 family proteins in carcinogenesis and the treatment of cancer. Apoptosis 2009; 14:584-596.
30. Campbell KJ, Tait SW. Targeting BCL-2 regulated apoptosis in cancer. Open Biol 2018; 8:180002-180012.
31. Boice A, Bouchier-Hayes L. Targeting apoptotic caspases in cancer. Biochim Biophys Acta Mol Cell Res 2020; 1867:118688-118726.
32. Ren X, Zhao B, Chang H, Xiao M, Wu Y, Liu Y. Paclitaxel suppresses proliferation and induces apoptosis through regulation of ROS and the AKT/MAPK signaling pathway in canine mammary gland tumor cells. Mol Med Rep 2018; 17:8289-8299.
33. Zheng M, Wu Z, Wu A, Huang Z, He N, Xie X. MiR-145 promotes TNF-α-induced apoptosis by facilitating the formation of RIP1-FADDcaspase-8 complex in triple-negative breast cancer. Tumor Biol 2016; 37:8599-8607.
34. Xin Z, Tong Z, Tan J, Liu C. MicroRNA-145-5p aggravates cell apoptosis and oxidative stress in tongue squamous cell carcinoma. Exp Ther Med 2021; 21:1-8.
35. Pan Y, Ye C, Tian Q, Yan S, Zeng X, Xiao C, et al. miR-145 suppresses the proliferation, invasion and migration of NSCLC cells by regulating the BAX/BCL-2 ratio and the caspase-3 cascade. Oncol Lett 2018; 15:4337-4343.
36. Mulcahy Levy JM, Thorburn A. Autophagy in cancer: Moving from understanding mechanism to improving therapy responses in patients. Cell Death Differ 2020; 27:843-857.
37. Grácio D, Magro F, Lima RT, Máximo V. An overview on the role of autophagy in cancer therapy. Hematol Med Oncol 2017; 2:1-4.
38. Lee Y, Na J, Lee MS, Cha EY, Sul JY, Park JB, et al. Combination of pristimerin and paclitaxel additively induces autophagy in human breast cancer cells via ERK1/2 regulation. Mol Med Rep 2018; 18:4281-4288.
39. Kim KW, Qiao J, Kim JY, Park K, Chung DH. Overexpression of microRNA-145 inhibits tumorigenesis through autophagy in chemotherapy and radiation resistant neuroblastoma cells. Oncoscience 2020; 7:1-9.
40. Shu C-H, Yang W, Shih Y-L, Kuo M-L, Huang T-S. Cell cycle G2/M arrest and activation of cyclin-dependent kinases associated with low-dose paclitaxel-induced sub-G1 apoptosis. Apoptosis 1997; 2:463-470.
41. Matsushita R, Yoshino H, Enokida H, Goto Y, Miyamoto K, Yonemori M, et al. Regulation of UHRF1 by dual-strand tumor-suppressor microRNA-145 (miR-145-5p and miR-145-3p): Inhibition of bladder cancer cell aggressiveness. Oncotarget 2016; 7:28460-28487.
42. Law PT-Y, Ching AK-K, Chan AW-H, Wong QW-L, Wong C-K, To K-F, et al. MiR-145 modulates multiple components of the insulin-like growth factor pathway in hepatocellular carcinoma. Carcinogenesis 2012; 33:1134-1141.
43. Wu J-s, Jiang J, Chen B-j, Wang K, Tang Y-l, Liang X-h. Plasticity of cancer cell invasion: Patterns and mechanisms. Transl Oncol 2021; 14:100899-100907.
44. Gonzalez-Avila G, Sommer B, Mendoza-Posada DA, Ramos C, Garcia-Hernandez AA, Falfan-Valencia R. Matrix metalloproteinases participation in the metastatic process and their diagnostic and therapeutic applications in cancer. Crit Rev Oncol Hematol 2019; 137:57-83.
45. Xu H, Niu M, Yuan X, Wu K, Liu A. CD44 as a tumor biomarker and therapeutic target. Exp Hematol Oncol 2020; 9:1-14.
46.Novak D, Hüser L, Elton JJ, Umansky V, Altevogt P, Utikal J. SOX2 in development and cancer biology. Semin Cancer Biol 2020;67:74-82.
47. Zhang S, Xiong X, Sun Y. Functional characterization of SOX2 as an anticancer target. Signal Transduct Target Ther 2020; 5:1-17.
48. Sun K, Tang XH, Xie YK. Paclitaxel combined with harmine inhibits the migration and invasion of gastric cancer cells through downregulation of cyclooxygenase‑2 expression. Oncol Lett 2015; 10:1649-1654.
49. Ding Y, Zhang C, Zhang J, Zhang N, Li T, Fang J, et al. miR-145 inhibits proliferation and migration of breast cancer cells by directly or indirectly regulating TGF-β1 expression. Int J Oncol 2017; 50:1701-1710.
50. Wang M, Zhang S. MiR-145 on the proliferation of ovarian cancer cells by regulating the expression of MMP-2/MMP-9. Cell Mol Biol 2021; 67:141-148.
51. Zeng J-F, Ma X-Q, Wang L-P, Wang W. MicroRNA-145 exerts tumor-suppressive and chemo-resistance lowering effects by targeting CD44 in gastric cancer. World J Gastroenterol 2017; 23:2337-2345.
52. Ozen M, Karatas OF, Gulluoglu S, Bayrak OF, Sevli S, Guzel E, et al. Overexpression of miR-145-5p inhibits proliferation of prostate cancer cells and reduces SOX2 expression. Cancer Invest 2015; 33:251-258.
53. Vaidya FU, Sufiyan Chhipa A, Mishra V, Gupta VK, Rawat SG, Kumar A, et al. Molecular and cellular paradigms of multidrug resistance in cancer. Cancer Rep 2022; 5:e1291-1310.
54. Lampis A, Hahne JC, Hedayat S, Valeri N. MicroRNAs as mediators of drug resistance mechanisms. Curr Opin  Pharmacol 2020; 54:44-50.
55. Safaei S, Amini M, Najjary S, Mokhtarzadeh A, Bolandi N, Saeedi H, et al. MiR-200c increases the sensitivity of breast cancer cells to Doxorubicin through downregulating MDR1 gene. Exp Mol Pathol 2022; 125:104753.